REAL-WORLD COSTS AND HEALTHCARE RESOURCE UTILIZATION FOR PATIENTS WITH METASTATIC NON-SMALL CELL LUNG CANCER AND PD-L1 TPS =50% IN THE UNITED STATES
Author(s)
Jhanelle E. Gray, MD1, Ryan Thaliffdeen, BS, MS, PharmD2, Samina Dhuliawala, BPharm, MS3, Indy Kaur Dhillon, PhD4, Marissa West, PharmD, RPh2, Amber Lee Curran, MS5, Sneha Nishtala, MS5, Emilie Scherrer, MSc5, Ankita Kaushik, PhD2.
1Moffitt Cancer Center, Tampa, FL, USA, 2Gilead Sciences, Inc., Foster City, CA, USA, 3IQVIA Inc., Durham, NC, USA, 4Gilead Sciences Europe Ltd, Uxbridge, Middlesex, United Kingdom, 5Tempus AI, Inc., Chicago, IL, USA.
1Moffitt Cancer Center, Tampa, FL, USA, 2Gilead Sciences, Inc., Foster City, CA, USA, 3IQVIA Inc., Durham, NC, USA, 4Gilead Sciences Europe Ltd, Uxbridge, Middlesex, United Kingdom, 5Tempus AI, Inc., Chicago, IL, USA.
OBJECTIVES: Despite treatment advances, few real-world studies have characterized US economic outcomes in metastatic non‒small cell lung cancer (mNSCLC) with programmed cell death-ligand 1 (PD-L1) tumor proportion score (TPS) ≥50% and no actionable genomic aberrations. This study evaluated all-cause and NSCLC-specific costs and healthcare resource utilization (HCRU) in this population.
METHODS: This retrospective, observational study used de-identified data from a multimodal database (Tempus AI, Inc.). Index date was the date of metastatic treatment initiation; follow-up was ≥3 months from index date until death, loss to follow-up, or study end. Eligible patients were 18−89 years old diagnosed with mNSCLC between January 1, 2016−September 15, 2025; had initiated systemic therapy for metastatic disease; and had PD-L1 TPS ≥50% with confirmed absence of EGFR, ALK, and ROS-1 aberrations. Costs and HCRU were examined during the post-index period and categorized by care setting. Visit costs (inpatient, outpatient, office) and HCRU were reported as mean (SD) per patient per month (PPPM).
RESULTS: Overall, 174 patients were included in this study (mean age, 68.9 years; male, 53.4%; White, 70.7%; Medicare, 66.7%; stage IV at diagnosis, 70.7%). Total all-cause costs were $13,810.75 (13,321.32) PPPM, with total NSCLC-specific costs of $9454.88 (11,775.37). The majority of total all-cause costs stemmed from outpatient visits ($3785.51 [$6944.91]) and office visits ($6985.88 [$10,235.20]), with corresponding NSCLC-specific costs of $1352.49 ($4200.70) and $6308.84 ($10,088.13). All-cause mean hospitalizations totaled 0.5 (2.35) PPPM and NSCLC-specific hospitalizations totaled 0.17 (0.87) PPPM, with length of stay of 2.20 (3.73) and 2.46 (4.02) days, respectively. There were 1.64 (1.81) and 1.93 (2.07) PPPM all-cause outpatient and office visits, respectively, and 0.61 (0.94) and 1.26 (1.70) PPPM NSCLC-specific visits, respectively.
CONCLUSIONS: All-cause and NSCLC-specific costs and HCRU, driven primarily by outpatient and office visits, demonstrate a considerable economic burden in the first-line setting for patients with PD-L1 TPS ≥50% without actionable genomic aberrations.
METHODS: This retrospective, observational study used de-identified data from a multimodal database (Tempus AI, Inc.). Index date was the date of metastatic treatment initiation; follow-up was ≥3 months from index date until death, loss to follow-up, or study end. Eligible patients were 18−89 years old diagnosed with mNSCLC between January 1, 2016−September 15, 2025; had initiated systemic therapy for metastatic disease; and had PD-L1 TPS ≥50% with confirmed absence of EGFR, ALK, and ROS-1 aberrations. Costs and HCRU were examined during the post-index period and categorized by care setting. Visit costs (inpatient, outpatient, office) and HCRU were reported as mean (SD) per patient per month (PPPM).
RESULTS: Overall, 174 patients were included in this study (mean age, 68.9 years; male, 53.4%; White, 70.7%; Medicare, 66.7%; stage IV at diagnosis, 70.7%). Total all-cause costs were $13,810.75 (13,321.32) PPPM, with total NSCLC-specific costs of $9454.88 (11,775.37). The majority of total all-cause costs stemmed from outpatient visits ($3785.51 [$6944.91]) and office visits ($6985.88 [$10,235.20]), with corresponding NSCLC-specific costs of $1352.49 ($4200.70) and $6308.84 ($10,088.13). All-cause mean hospitalizations totaled 0.5 (2.35) PPPM and NSCLC-specific hospitalizations totaled 0.17 (0.87) PPPM, with length of stay of 2.20 (3.73) and 2.46 (4.02) days, respectively. There were 1.64 (1.81) and 1.93 (2.07) PPPM all-cause outpatient and office visits, respectively, and 0.61 (0.94) and 1.26 (1.70) PPPM NSCLC-specific visits, respectively.
CONCLUSIONS: All-cause and NSCLC-specific costs and HCRU, driven primarily by outpatient and office visits, demonstrate a considerable economic burden in the first-line setting for patients with PD-L1 TPS ≥50% without actionable genomic aberrations.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
EE93
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, Oncology